HER2-negative Breast Cancer Clinical Trial
— DIRECT-2Official title:
DIRECT-2: Fasting Mimicking Diet Program to ImpRovE ChemoTherapy in HR+, HER2- Breast Cancer
Verified date | November 2023 |
Source | Leiden University Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
In preclinical research, short-term fasting (STF) protects tumor-bearing mice against the toxic effects of chemotherapy, improves the CD8+ effector T-cell intratumor infiltration, while enhancing the chemotherapy efficacy. Short-term use of a "fasting-mimicking diet" (FMD) caused a major increase in the efficacy of cancer treatment in mice comparable to STF. In humans, the investigators recently performed a multicenter randomized phase II trial showing that patients with Human Epidermal growth factor Receptor 2 (HER2) negative breast cancer treated with neoadjuvant chemotherapy and FMD displayed a better radiological response and a better pathological response (90-100% vs <90% tumor cell reduction) than patients treated with chemotherapy without FMD (de Groot, Nat Commun 2020; NCT02126449). Therefore these findings will be validated in a phase 3 trial with the underlying hypothesis that FMD during neoadjuvant chemotherapy for breast cancer improves clinical outcomes, potentially due to improved local immunity.
Status | Suspended |
Enrollment | 10 |
Est. completion date | January 1, 2024 |
Est. primary completion date | January 1, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Clinical stage II-III (cT1cN+ or =T2 any cN, cM0), HR+, HER2- breast cancer - Detectable and measurable disease (breast and/or lymph nodes) - World Health Organization (WHO) performance status 0-2 - Adequate organ function assessed by standard pre-treatment assessment: - Adequate bone marrow function: white blood cells (WBCs) =3.0 x 109/l, neutrophils =1.5 x 109/l, platelets =100 x 109/l - Adequate liver function: bilirubin =1.5 x upper limit of normal (UNL) range, ALAT and/or ASAT =2.5 x UNL, Alkaline Phosphatase =5 x UNL - Adequate renal function: the calculated creatinine clearance should be =50 mL/min - Available for treatment and follow-up - Written informed-consent - Willing to fill in Quality Of Life and Cognition questionnaires - Ability to read and understand Dutch language, accessibility to a computer with internet connection and independent use of computer Exclusion Criteria: - Patient history of invasive or ipsilateral non-invasive breast cancer - Active malignancy in the last 5 years, with the exclusion of basal cell carcinoma or pre-invasive cervical neoplasia/dysplasia. - Body mass index (BMI) < 18.5 kg/m2 - Pregnancy or lactating - Food allergy for ingredients of FMD (nuts, soy, honey) - A metabolic condition affecting gluconeogenesis or adaptation to periodic fasting. (Diabetes Mellitus for example) |
Country | Name | City | State |
---|---|---|---|
Netherlands | Noordwest Ziekenhuisgroep | Alkmaar | |
Netherlands | Rode Kruis ziekenhuis | Beverwijk | |
Netherlands | Alexander Monro Ziekenhuis | Bilthoven | |
Netherlands | Reinier de Graaf ziekenhuis | Delft | |
Netherlands | Deventer Ziekenhuis | Deventer | |
Netherlands | Ziekenhuis Gelderse Vallei | Ede | |
Netherlands | Leiden University Medical Center | Leiden |
Lead Sponsor | Collaborator |
---|---|
Leiden University Medical Center | Borstkanker Onderzoek Groep, Comprehensive Cancer Centre The Netherlands, Koningin Wilhelmina Fonds, L-Nutra Inc, The Netherlands Cancer Institute, World Cancer Research Fund International |
Netherlands,
de Groot S, Lugtenberg RT, Cohen D, Welters MJP, Ehsan I, Vreeswijk MPG, Smit VTHBM, de Graaf H, Heijns JB, Portielje JEA, van de Wouw AJ, Imholz ALT, Kessels LW, Vrijaldenhoven S, Baars A, Kranenbarg EM, Carpentier MD, Putter H, van der Hoeven JJM, Nortier JWR, Longo VD, Pijl H, Kroep JR; Dutch Breast Cancer Research Group (BOOG). Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial. Nat Commun. 2020 Jun 23;11(1):3083. doi: 10.1038/s41467-020-16138-3. — View Citation
de Groot S, Pijl H, van der Hoeven JJM, Kroep JR. Effects of short-term fasting on cancer treatment. J Exp Clin Cancer Res. 2019 May 22;38(1):209. doi: 10.1186/s13046-019-1189-9. — View Citation
Di Biase S, Lee C, Brandhorst S, Manes B, Buono R, Cheng CW, Cacciottolo M, Martin-Montalvo A, de Cabo R, Wei M, Morgan TE, Longo VD. Fasting-Mimicking Diet Reduces HO-1 to Promote T Cell-Mediated Tumor Cytotoxicity. Cancer Cell. 2016 Jul 11;30(1):136-146. doi: 10.1016/j.ccell.2016.06.005. — View Citation
Lugtenberg RT, de Groot S, Kaptein AA, Fischer MJ, Kranenbarg EM, Carpentier MD, Cohen D, de Graaf H, Heijns JB, Portielje JEA, van de Wouw AJ, Imholz ALT, Kessels LW, Vrijaldenhoven S, Baars A, Fiocco M, van der Hoeven JJM, Gelderblom H, Longo VD, Pijl H, Kroep JR; Dutch Breast Cancer Research Group (BOOG). Quality of life and illness perceptions in patients with breast cancer using a fasting mimicking diet as an adjunct to neoadjuvant chemotherapy in the phase 2 DIRECT (BOOG 2013-14) trial. Breast Cancer Res Treat. 2021 Feb;185(3):741-758. doi: 10.1007/s10549-020-05991-x. Epub 2020 Nov 11. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Biomarker analysis to predict treatment outcome | Genetic and/or epigenetic analysis will be performed on blood samples by for example PCR and/or GWAS technique. | 6 years | |
Other | Optional Bioelectrical Impedance Analysis (BIA) for participants at the Leiden University Medical Center (LUMC) to investigate the change in body composition in both treatment arms. | 4.5 years | ||
Primary | Pathological response rate (pCR). Both percentage of pCR and 90-100% tumor loss according to Miller & Payne | 4.5 years | ||
Primary | Objective response rate assessed by MRI (RECIST1.1) after 4 ddAC cycles and at the end of chemotherapy | 4.5 years | ||
Secondary | Determine the effect of treatment on the 3 and 5 year Event-free survival (EFS) and Overall survival (OS) | 7.5 and 9.5 years | ||
Secondary | Adverse events =grade 3 (maximum of total) difference between treatment arms during neoadjuvant chemotherapy (ddAC, paclitaxel and total). | 4.5 years | ||
Secondary | Quality of Life assessed by online questionnaires (EORTC QLQ-C30, EORTC QLQ-BR23), burden of therapy (Distress Thermometer) and Illness Perceptions (B-IPQ) | Validated online questionnaires take place at baseline, after 4 ddAC cycles, before surgery and 6 months after surgery. | 5 years | |
Secondary | Cognition assessed by Amsterdam Cognition Scan (ACS) online battery consisting of 7 online neuropsychological tests | online questionnaires take place at baseline, before surgery and 6 months after surgery. | 5 years | |
Secondary | Determine the effect of FMD on local immunomodulation and tumor immunity | By analyzing the immune-composition and gene-expression profile using multispectral Vectra imaging and Nanostring analyses respectively, in tumor samples taken at baseline (diagnostic), after 4 cycles and resection specimen | 6 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05383196 -
Onvansertib + Paclitaxel In TNBC
|
Phase 1/Phase 2 | |
Completed |
NCT02371174 -
Post-Marketing Surveillance Study of Eribulin on the Status and Factors for the Development of Peripheral Neuropathy in Japan.
|
||
Completed |
NCT02225470 -
Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes
|
Phase 3 | |
Recruiting |
NCT05173103 -
Retrospective Study of 2nd-line Therapies After CDK4/6i + Hormonal Therapy in HR+/HER2- Advanced Breast Cancer
|
||
Active, not recruiting |
NCT04448886 -
Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC
|
Phase 2 | |
Not yet recruiting |
NCT04498793 -
Study of Tislelizumab Plus Chemotherapy vs Chemotherapy as Perioperative Treatment in Participants With HER2 Negative Breast Cancer
|
Phase 2 | |
Completed |
NCT01705691 -
Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer
|
Phase 2 | |
Terminated |
NCT01368263 -
Goserelin and Letrozole or Anastrozole in Premenopausal Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer
|
Phase 2 | |
Recruiting |
NCT04576143 -
Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer
|
Phase 2/Phase 3 | |
Completed |
NCT05054374 -
A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT05467891 -
Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
|
Phase 2 | |
Recruiting |
NCT04660435 -
To Identify Primary Resistance to CDK4/6 Inhibitors in Breast Cancer
|
||
Completed |
NCT02015559 -
Mucoadhesive Oral Wound Rinse in Preventing and Treating Stomatitis in Patients With ER- or PR-Positive Metastatic or Locally Recurrent Breast Cancer That Cannot be Removed by Surgery Receiving Everolimus
|
Phase 2 | |
Completed |
NCT04504916 -
A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Solid Tumors (MK-2140-002)
|
Phase 2 | |
Terminated |
NCT04738292 -
Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study)
|
Phase 2 | |
Recruiting |
NCT05982093 -
Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer
|
Phase 2 | |
Recruiting |
NCT05396612 -
Role of the Immune Environment in Response to Therapy in Breast Cancer
|
||
Active, not recruiting |
NCT04595565 -
Sacituzumab Govitecan in Primary HER2-negative Breast Cancer
|
Phase 3 | |
Terminated |
NCT01234532 -
Entinostat and Anastrozole in Treating Postmenopausal Women With TNBC That Can Be Removed by Surgery
|
Phase 2 | |
Terminated |
NCT01217411 -
RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer
|
Phase 1 |